PD-1 Knockout Could Be Caribou’s Key To Allo CAR-T Success
Early Response Rate Exceeds Competitors
Executive Summary
While it is still early days for Caribou, early signs suggest it could have the first off-the-shelf program to rival established CAR-T therapies.
You may also be interested in...
Caribou CEO On The Evolution Of CAR-T Treatment
Rachel Haurwitz, president and CEO of CRISPR-focused biotech Caribou, sat down with In Vivo to reflect on the thrill of the early days of CRISPR technology, Caribou’s second-generation approach, and the benefits of being a CEO with no prior corporate leadership experience.
Caribou Hit By Familiar Allo CAR-T Durability Problems
Like some of its allo CAR-T rivals, CB-010’s early promise has fallen away, but Caribou still hopes a higher dose can bring with it real durability of response.
Bayer Shuffles Atara’s CAR-Ts Out Of Its Cell Therapy Deck
Bayer is handing back rights to two early-stage off-the-shelf CAR-Ts to Atara, but the split could still be good news for the biotech company.